Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
Identifieur interne : 001571 ( Main/Exploration ); précédent : 001570; suivant : 001572Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
Auteurs : Kevin St. P. Mcnaught [États-Unis] ; Daniel P. Perl [États-Unis] ; Anna-Liisa Brownell [États-Unis] ; C. Warren Olanow [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2004-07.
Abstract
Environmental toxins have been implicated in the etiology of Parkinson's disease. Recent findings of defects in the ubiquitin‐proteasome system in hereditary and sporadic forms of the illness suggest that environmental proteasome inhibitors are candidate PD‐inducing toxins. Here, we systemically injected six doses of naturally occurring (epoxomicin) or synthetic (Z‐lle‐Glu(OtBu)‐Ala‐Leu‐al [PSI]) proteasome inhibitors into adult rats over a period of 2 weeks. After a latency of 1 to 2 weeks, animals developed progressive parkinsonism with bradykinesia, rigidity, tremor, and an abnormal posture, which improved with apomorphine treatment. Positron emission tomography demonstrated reduced carbon‐11‐labeled 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)tropane (CFT) binding to dopaminergic nerve terminals in the striatum, indicative of degeneration of the nigrostriatal pathway. Postmortem analyses showed striatal dopamine depletion and dopaminergic cell death with apoptosis and inflammation in the substantia nigra pars compacta. In addition, neurodegeneration occurred in the locus coeruleus, dorsal motor nucleus of the vagus, and the nucleus basalis of Meynert. At neurodegenerative sites, intracytoplasmic, eosinophilic, α‐synuclein/ubiquitin–containing, inclusions resembling Lewy bodies were present in some of the remaining neurons. This animal model induced by proteasome inhibitors closely recapitulates key features of PD and may be valuable in studying etiopathogenic mechanisms and putative neuroprotective therapies for the illness. Ann Neurol 2004
Url:
DOI: 10.1002/ana.20186
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease</title><author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name></author><author><name sortKey="Perl, Daniel P" sort="Perl, Daniel P" uniqKey="Perl D" first="Daniel P." last="Perl">Daniel P. Perl</name></author><author><name sortKey="Brownell, Anna Iisa" sort="Brownell, Anna Iisa" uniqKey="Brownell A" first="Anna-Liisa" last="Brownell">Anna-Liisa Brownell</name></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4471D455ACBE5BCD05D4C0EB04C45BD527FA1E03</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/ana.20186</idno><idno type="url">https://api.istex.fr/document/4471D455ACBE5BCD05D4C0EB04C45BD527FA1E03/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002B08</idno><idno type="wicri:Area/Main/Curation">002744</idno><idno type="wicri:Area/Main/Exploration">001571</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease</title><author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, Neuropathology Division, Mount Sinai School of Medicine, New York</wicri:cityArea></affiliation></author><author><name sortKey="Perl, Daniel P" sort="Perl, Daniel P" uniqKey="Perl D" first="Daniel P." last="Perl">Daniel P. Perl</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Pathology, Neuropathology Division, Mount Sinai School of Medicine, New York</wicri:cityArea></affiliation></author><author><name sortKey="Brownell, Anna Iisa" sort="Brownell, Anna Iisa" uniqKey="Brownell A" first="Anna-Liisa" last="Brownell">Anna-Liisa Brownell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, Neuropathology Division, Mount Sinai School of Medicine, New York</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-07">2004-07</date><biblScope unit="volume">56</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="149">149</biblScope><biblScope unit="page" to="162">162</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">4471D455ACBE5BCD05D4C0EB04C45BD527FA1E03</idno><idno type="DOI">10.1002/ana.20186</idno><idno type="ArticleID">ANA20186</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Environmental toxins have been implicated in the etiology of Parkinson's disease. Recent findings of defects in the ubiquitin‐proteasome system in hereditary and sporadic forms of the illness suggest that environmental proteasome inhibitors are candidate PD‐inducing toxins. Here, we systemically injected six doses of naturally occurring (epoxomicin) or synthetic (Z‐lle‐Glu(OtBu)‐Ala‐Leu‐al [PSI]) proteasome inhibitors into adult rats over a period of 2 weeks. After a latency of 1 to 2 weeks, animals developed progressive parkinsonism with bradykinesia, rigidity, tremor, and an abnormal posture, which improved with apomorphine treatment. Positron emission tomography demonstrated reduced carbon‐11‐labeled 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)tropane (CFT) binding to dopaminergic nerve terminals in the striatum, indicative of degeneration of the nigrostriatal pathway. Postmortem analyses showed striatal dopamine depletion and dopaminergic cell death with apoptosis and inflammation in the substantia nigra pars compacta. In addition, neurodegeneration occurred in the locus coeruleus, dorsal motor nucleus of the vagus, and the nucleus basalis of Meynert. At neurodegenerative sites, intracytoplasmic, eosinophilic, α‐synuclein/ubiquitin–containing, inclusions resembling Lewy bodies were present in some of the remaining neurons. This animal model induced by proteasome inhibitors closely recapitulates key features of PD and may be valuable in studying etiopathogenic mechanisms and putative neuroprotective therapies for the illness. Ann Neurol 2004</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name></region><name sortKey="Brownell, Anna Iisa" sort="Brownell, Anna Iisa" uniqKey="Brownell A" first="Anna-Liisa" last="Brownell">Anna-Liisa Brownell</name><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><name sortKey="Perl, Daniel P" sort="Perl, Daniel P" uniqKey="Perl D" first="Daniel P." last="Perl">Daniel P. Perl</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001571 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001571 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4471D455ACBE5BCD05D4C0EB04C45BD527FA1E03
|texte= Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |